Jarno Hoekman
Cited by
Cited by
Research collaboration at a distance: Changing spatial patterns of scientific collaboration within Europe
J Hoekman, K Frenken, RJW Tijssen
Research Policy 39 (5), 662-673, 2010
The geography of collaborative knowledge production in Europe
J Hoekman, K Frenken, F Van Oort
The annals of regional science 43, 721-738, 2009
Spatial scientometrics: Towards a cumulative research program
K Frenken, S Hardeman, J Hoekman
Journal of informetrics 3 (3), 222-232, 2009
Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis
HJL Heerspink, TF Kröpelin, J Hoekman, D De Zeeuw
Journal of the American Society of Nephrology 26 (8), 2055-2064, 2015
Big Pharma, Little Science? A bibliometric perspective on big pharma’s R&D decline
I Rafols, M Hopkins, J Hoekman, P Nightingale, A Perianes-Rodriguez, ...
Technological Forecasting and Social Change, 2012
Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous …
HH Ampadu, J Hoekman, ML de Bruin, SN Pal, S Olsson, D Sartori, ...
Drug safety 39, 335-345, 2016
Acquisition of European research funds and its effect on international scientific collaboration
J Hoekman, T Scherngell, K Frenken, R Tijssen
Journal of economic geography 13 (1), 23-52, 2013
What drives university research performance? An analysis using the CWTS Leiden Ranking data
K Frenken, GJ Heimeriks, J Hoekman
Journal of informetrics 11 (3), 859-872, 2017
Challenges in advanced therapy medicinal product development: a survey among companies in Europe
RMT Ten Ham, J Hoekman, AM Hövels, AW Broekmans, HGM Leufkens, ...
Molecular Therapy-Methods & Clinical Development 11, 121-130, 2018
Death of distance in science? A gravity approach to research collaboration
K Frenken, J Hoekman, S Kok, R Ponds, F van Oort, J van Vliet
Innovation networks: New approaches in modelling and analyzing, 43-57, 2009
Use of the conditional marketing authorization pathway for oncology medicines in Europe
J Hoekman, WPC Boon, JC Bouvy, HC Ebbers, JP de Jong, ML De Bruin
Clinical Pharmacology & Therapeutics 98 (5), 534-541, 2015
Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EU
J Hoekman, TT Klamer, AK Mantel‐Teeuwisse, HGM Leufkens, ...
British journal of clinical pharmacology 82 (1), 213-226, 2016
The geography of scientific citations
ML Wuestman, J Hoekman, K Frenken
Research Policy 48 (7), 1771-1780, 2019
Spatial scientometrics and scholarly impact: A review of recent studies, tools, and methods
K Frenken, J Hoekman
Measuring scholarly impact: methods and practice, 127-146, 2014
Convergence in an enlarged Europe: the role of network cities.
K Frenken, J Hoekman
Tijdschrift voor Economische en Sociale Geografie (Journal of Economic …, 2006
The Geographical Distribution of Leadership in Globalized Clinical Trials
J Hoekman, K Frenken, D de Zeeuw, HL Heerspink
PLOS ONE 7 (10), e45984, 2012
Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
I Lipska, J Hoekman, N McAuslane, HGM Leufkens, AM Hövels
Clinical Pharmacology & Therapeutics 98 (5), 489-491, 2015
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings
RMT Ten Ham, AM Hövels, J Hoekman, GWJ Frederix, HGM Leufkens, ...
Cytotherapy 22 (7), 388-397, 2020
Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences
HH Ampadu, J Hoekman, D Arhinful, M Amoama-Dapaah, HGM Leufkens, ...
Globalization and health 14, 1-17, 2018
The importance of geographical distance to different types of R&D collaboration in the pharmaceutical industry
F Bignami, P Mattsson, J Hoekman
Industry and Innovation 27 (5), 513-537, 2020
The system can't perform the operation now. Try again later.
Articles 1–20